X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (16383) 16383
Book Review (2419) 2419
Publication (1152) 1152
Book Chapter (91) 91
Conference Proceeding (25) 25
Dissertation (14) 14
Book / eBook (11) 11
Newsletter (10) 10
Magazine Article (5) 5
Data Set (3) 3
Newspaper Article (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (14724) 14724
humans (13393) 13393
female (8118) 8118
male (7316) 7316
middle aged (6465) 6465
oncology (6150) 6150
adenocarcinoma (6106) 6106
cancer (5972) 5972
aged (5711) 5711
adult (4131) 4131
adenocarcinoma - pathology (3953) 3953
animals (3011) 3011
carcinoma (2833) 2833
tumors (2831) 2831
prognosis (2758) 2758
surgery (2755) 2755
aged, 80 and over (2297) 2297
metastasis (2242) 2242
research (2027) 2027
chemotherapy (1993) 1993
neoplasm staging (1938) 1938
analysis (1919) 1919
expression (1898) 1898
medicine & public health (1897) 1897
abridged index medicus (1878) 1878
pathology (1849) 1849
mice (1847) 1847
care and treatment (1749) 1749
adenocarcinoma - surgery (1699) 1699
pancreatic cancer (1650) 1650
immunohistochemistry (1629) 1629
survival (1562) 1562
adenocarcinoma - metabolism (1558) 1558
health aspects (1498) 1498
diagnosis (1478) 1478
cell line, tumor (1471) 1471
adenocarcinoma - drug therapy (1470) 1470
treatment outcome (1465) 1465
adenocarcinoma - genetics (1443) 1443
retrospective studies (1435) 1435
lung cancer (1323) 1323
gastroenterology & hepatology (1319) 1319
risk factors (1235) 1235
lung neoplasms - pathology (1232) 1232
genetic aspects (1183) 1183
gene expression (1147) 1147
follow-up studies (1131) 1131
survival rate (1119) 1119
apoptosis (1054) 1054
pancreatic neoplasms - pathology (1035) 1035
adenocarcinoma - mortality (1034) 1034
adenocarcinoma - secondary (1034) 1034
development and progression (1029) 1029
colorectal cancer (1020) 1020
adenocarcinoma - diagnosis (1015) 1015
proteins (994) 994
medicine (985) 985
mutation (921) 921
breast-cancer (919) 919
cell biology (918) 918
research article (916) 916
patients (838) 838
therapy (830) 830
adenocarcinoma - therapy (823) 823
multidisciplinary sciences (823) 823
article (817) 817
medical prognosis (810) 810
cells (803) 803
gene expression regulation, neoplastic (800) 800
antineoplastic combined chemotherapy protocols - therapeutic use (771) 771
lymphatic metastasis (765) 765
survival analysis (757) 757
metastases (737) 737
radiotherapy (737) 737
neoplasm invasiveness (732) 732
cancer therapies (731) 731
prostate cancer (725) 725
oncology, experimental (717) 717
biochemistry & molecular biology (707) 707
cancer research (699) 699
medical research (696) 696
angiogenesis (694) 694
radiology, nuclear medicine & medical imaging (688) 688
stomach neoplasms - pathology (687) 687
studies (685) 685
biomarkers (680) 680
prostatic neoplasms - pathology (679) 679
stomach cancer (671) 671
diagnosis, differential (666) 666
gastroenterology (666) 666
disease-free survival (653) 653
prospective studies (651) 651
colorectal-cancer (635) 635
science (633) 633
combined modality therapy (631) 631
lung neoplasms - genetics (614) 614
neoplasm metastasis (613) 613
tumor cells, cultured (613) 613
urology & nephrology (611) 611
carcinoma, squamous cell - pathology (607) 607
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16431) 16431
Japanese (18) 18
Chinese (15) 15
German (10) 10
French (9) 9
Polish (4) 4
Spanish (4) 4
Russian (3) 3
Croatian (1) 1
Italian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 03/2013, Volume 19, Issue 5, pp. 1213 - 1224
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2015, Volume 26, Issue 10, pp. 2141 - 2149
The immune system is important in epithelial ovarian cancer (EOC). Interleukin-6 is associated with chemoresistance and an immune-suppressive tumor... 
Tumor immunity | Immunotherapy | Chemoresistance | Interleukin-6 | Ovarian cancer | Prognosis | Follow-Up Studies | Adenocarcinoma, Mucinous - pathology | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Receptors, Interleukin-6 - antagonists & inhibitors | Cystadenocarcinoma, Serous - pathology | Adenocarcinoma, Clear Cell - blood | Cystadenocarcinoma, Serous - drug therapy | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Adenocarcinoma, Mucinous - blood | Interleukin-6 - blood | Doxorubicin - analogs & derivatives | Adult | Female | Adenocarcinoma, Mucinous - drug therapy | Neoplasm Recurrence, Local - blood | Ovarian Neoplasms - drug therapy | Doxorubicin - administration & dosage | Cystadenocarcinoma, Serous - blood | CA-125 Antigen - blood | Enzyme-Linked Immunosorbent Assay | Neoplasm Invasiveness | Carboplatin - administration & dosage | Ovarian Neoplasms - blood | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Biomarkers, Tumor - blood | Interferon-alpha - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Adenocarcinoma, Clear Cell - pathology | Aged | Neoplasm Staging | Endometrial Neoplasms - blood | Interferon-gamma - blood | Adenocarcinoma, Clear Cell - drug therapy | Index Medicus
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 08/2018, Volume 150, Issue 2, pp. 247 - 252
Journal Article
BMC Cancer, ISSN 1471-2407, 03/2009, Volume 9, Issue 1, pp. 82 - 82
Background: Sunitinib is a protein tyrosine kinase-inhibitor targeting VEGFR, c-kit and PDGFR. It has been approved for the treatment of metastatic renal-cell... 
PROTEIN | ONCOLOGY | TUMOR | TYROSINE KINASE INHIBITOR | ANTITUMOR-ACTIVITY | FACTOR RECEPTOR | CANCER | SU11248 | ENDOTHELIAL GROWTH-FACTOR | Prognosis | Adenocarcinoma, Clear Cell - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Adenocarcinoma, Clear Cell - blood | Kidney Neoplasms - blood | Neovascularization, Pathologic - blood | Kidney Neoplasms - diagnosis | Neoplasm Metastasis | Platelet-Derived Growth Factor - biosynthesis | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Pyrroles - therapeutic use | Receptors, Platelet-Derived Growth Factor - antagonists & inhibitors | Vascular Endothelial Growth Factor A - blood | Vascular Endothelial Growth Factor Receptor-2 - blood | Treatment Outcome | Adenocarcinoma, Clear Cell - diagnosis | Kidney Neoplasms - mortality | Biomarkers, Tumor - blood | Disease-Free Survival | Indoles - therapeutic use | Kidney Neoplasms - pathology | Adenocarcinoma, Clear Cell - pathology | Aged | Kidney Neoplasms - drug therapy | Biomarkers, Tumor - biosynthesis | Adenocarcinoma, Clear Cell - drug therapy | Physiological aspects | Development and progression | Carcinoma, Renal cell | Diagnosis | Research | Drug therapy | Vascular endothelial growth factor | Index Medicus
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 4/2007, Volume 59, Issue 5, pp. 561 - 574
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2013, Volume 19, Issue 18, pp. 5227 - 5239
Purpose: The aim of this study was to identify and validate novel predictive and/or prognostic serum proteomic biomarkers in patients with epithelial ovarian... 
PHASE-III TRIAL | BREAST-CANCER | MESOTHELIN | ONCOLOGY-GROUP | THERAPY | ONCOLOGY | METASTATIC COLORECTAL-CANCER | RENAL-CELL CARCINOMA | PLUS BEVACIZUMAB | CHEMOTHERAPY | ENDOTHELIAL GROWTH-FACTOR | Prognosis | Follow-Up Studies | Endometrial Neoplasms - mortality | Peritoneal Neoplasms - blood | Adenocarcinoma, Clear Cell - mortality | Humans | Middle Aged | Ovarian Neoplasms - mortality | Adenocarcinoma, Clear Cell - blood | Cystadenocarcinoma, Serous - drug therapy | Bevacizumab | Patient Selection | Fallopian Tube Neoplasms - blood | Peritoneal Neoplasms - drug therapy | Adenocarcinoma, Mucinous - blood | Angiogenesis Inhibitors - therapeutic use | Chromatography, Liquid | Adult | Female | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | Adenocarcinoma, Mucinous - drug therapy | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Cystadenocarcinoma, Serous - blood | Antibodies, Monoclonal, Humanized - therapeutic use | Ovarian Neoplasms - blood | Survival Rate | Peritoneal Neoplasms - mortality | Biomarkers, Tumor - blood | Adenocarcinoma, Mucinous - mortality | Validation Studies as Topic | Fallopian Tube Neoplasms - mortality | Cystadenocarcinoma, Serous - mortality | Endometrial Neoplasms - drug therapy | Aged | Neoplasm Staging | Endometrial Neoplasms - blood | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Index Medicus | bevacizumab | predictive | ICON7 | proteomics | serum | biomarkers
Journal Article
International Journal of Cancer, ISSN 0020-7136, 02/2005, Volume 113, Issue 5, pp. 782 - 788
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2016, Volume 11, Issue 10, pp. e0165609 - e0165609
Background There is currently no reliable serum biomarker for ovarian clear cell carcinoma (CCC), a highly lethal histological subtype of epithelial ovarian... 
MENSTRUAL-CYCLE | TUMOR-MARKERS | CA 125 | PROGNOSIS | ADENOCARCINOMA | MULTIDISCIPLINARY SCIENCES | PLACENTAL PROTEIN-5 | RISK | IDENTIFICATION | CANCER | ENDOMETRIOSIS | Prognosis | Age Factors | Humans | Middle Aged | Menstrual Cycle | Adenocarcinoma, Clear Cell - blood | Biomarkers, Tumor | Young Adult | Neoplasms, Glandular and Epithelial - blood | Genital Diseases, Female - blood | Neoplasm Grading | Aged, 80 and over | Adult | Female | Neoplasms, Glandular and Epithelial - diagnosis | Adenocarcinoma, Clear Cell - surgery | Reproducibility of Results | CA-125 Antigen - blood | Ovarian Neoplasms - diagnosis | Ovarian Neoplasms - blood | Glycoproteins - blood | Adenocarcinoma, Clear Cell - diagnosis | Neoplasms, Glandular and Epithelial - surgery | Carcinoma, Ovarian Epithelial | Genital Diseases, Female - diagnosis | ROC Curve | Aged | Neoplasm Staging | Ovarian Neoplasms - surgery | Preoperative Period | Carcinoma | Diagnostic equipment (Medical) | Ovarian cancer | Cancer | Health care | Ovarian carcinoma | Tissue factor | Oncology | Medical diagnosis | Training | Proteins | Uterus | Surgery | Life sciences | Bioindicators | Medical research | Antigens | Menstruation | Gynecology | Endometriosis | Gene expression | Patients | Obstetrics | Discrimination | Hospitals | Inhibitors | Womens health | Medical prognosis | Epigenetics | Biomarkers | Diagnostic systems | Tumors | Index Medicus
Journal Article
Journal Article